ZEN-BIO, INC.

Basic Information

P.O. BOX 13888
3200 CHAPEL HILL-NELSON BLVD.
RTP, NC, 27709-3888

Company Profile

n/a

Additional Details

Field Value
DUNS: 799863261
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. IGF OT IGF HIGH CONTENT SCREENING FOR HUMAN PRIMARY PANCREATIC CELL TYPE SPECIFIC TOXICANTS

    Amount: $224,901.00

    Not Available

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Development and validation of a human brown adipocyte system

    Amount: $224,320.00

    DESCRIPTION provided by applicant The activation and recruitment of brown adipose tissue has become an exciting target in the fight against obesity and its related metabolic diseases Brown adipose ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Development of a drug discovery platform for human islets

    Amount: $1,754,814.00

    DESCRIPTION provided by applicant Diabetes and diabetes related co morbidities are at epidemic proportions and an enormous burden to our healthcare system Although there has been significant progr ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  4. Selective Fyn kinase inhibitors for treatment of metabolic disease

    Amount: $1,498,715.00

    DESCRIPTION provided by applicant Metabolic diseases such as type diabetes T D obesity and their related co morbidities have reached epidemic proportions worldwide While progress continues to ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  5. Identification of potent and selective GLI1 inhibitors

    Amount: $289,934.00

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in ...

    STTR Phase I 2013 Department of Health and Human Services
  6. Development of a Drug Discovery Platform for Human Islets

    Amount: $462,386.00

    DESCRIPTION (provided by applicant): Diabetes and diabetes-related co-morbidities are at epidemic proportions and an enormous burden to our healthcare system. Although there has been significant progr ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Development of a human skeletal muscle cell-based high throughput screen for musc

    Amount: $251,144.00

    DESCRIPTION (provided by applicant): Skeletal muscle wasting is a serious condition prevalent in the aging population (sarcopenia) and in a variety of specific diseases. This condition results in loss ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Selective Fyn kinase inhibitors for treatment of metabolic disease

    Amount: $350,681.00

    DESCRIPTION (provided by applicant): Metabolic diseases such as type 2 diabetes (T2D), obesity and their related co-morbidities have reached epidemic proportions worldwide. While progress continues to ...

    SBIR Phase I 2011 Department of Health and Human Services
  9. Diabetes Therapies from Adipose Derived Stem Cells

    Amount: $363,202.00

    DESCRIPTION (provided by applicant): Diabetes affects the lives of hundreds of millions of people worldwide and the incidence rate is continuing to rise. About 8% of the US population is estimated to ...

    SBIR Phase I 2010 Department of Health and Human Services
  10. Commercialization of Human Mammary Basal / Luminal Cell System for Research

    Amount: $1,285,560.00

    DESCRIPTION (provided by applicant): Breast cancer is the second most common cancer among women. Roughly 190,000 women in the U.S. will be diagnosed with breast cancer in 2009, and 40,000 will die. Th ...

    SBIR Phase II 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government